ApaTech steps up US synthetic bone graft drive
This article was originally published in Clinica
Executive Summary
UK synthetic bone graft developer ApaTech is stepping up for the next stage in its own development with the establishment of US operations. The London, UK-based spin-out of Queen Mary University recently obtained FDA 510(k) clearance for its Pore-Si and ApaPore products, and is aiming to "capture significant market share in the US", according to ApaTech Inc's new president, Steve Czick.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.